Please provide your email address to receive an email when new articles are posted on . O’Brien: An initial response is to consider the individual’s insurance formulary. However, when an insurance ...

A century ago, type 1 diabetes was a death sentence. Children diagnosed rarely survived more than a year or two, wasting away as their bodies starved despite food. Then, in 1921, in a modest lab in ...

LEHI, Utah, Oct. 16, 2025 /PRNewswire/ -- Non-profit pharmaceutical company Civica will launch an affordable long-acting insulin – insulin glargine-yfgn in pre-filled pens – at the lowest list price ...

On February 14, 2025, the U.S. Food and Drug Administration (“FDA”) approved Sanofi-Aventis U.S. LLC’s (“Sanofi”) MERILOG™ (insulin-aspart-szjj), a biosimilar to Novo Nordisk A/S’s (“Novo Nordisk”) ...

Novo Nordisk A/S (NYSE:NVO) has reportedly discontinued its long-acting insulin Levemir in the U.S., attributing the decision to manufacturing constraints, reduced patient access, and the availability ...

HHS officials are moving forward with a plan to produce 4.8 million doses of H5N1 avian flu vaccine; Novo Nordisk’s long-acting insulin had a greater risk of excessively lowering patients’ blood sugar ...

Hello! I'm covering Niagara County for 7 News WKBW. If you have a story idea, please email me at [email protected] AMHERST, N.Y. — Dr. Paresh Dandona at the University at Buffalo Jacobs School of ...

Please provide your email address to receive an email when new articles are posted on . Two experts recently discussed situations in which ultra-long-acting insulins may be a good choice for patients ...

On May 24, an FDA advisory committee will meet to discuss the safety profile of Awiqli (insulin icodec), Novo Nordisk’s long-lasting insulin, after a study showed the drug poses an increased risk of ...

Three U.S. Senators say they are "alarmed" Novo Nordisk discontinued U.S. sales of a popular insulin brand and are demanding answers from the pharmaceutical giant they say left patients without an ...

Inhaled Technosphere insulin (TI) failed to meet noninferiority for HbA1c vs subcutaneous rapid-acting analog (RAA) insulin in youth.

Rows of glass vials in a biologics laboratory in Sweden. Photographer: Mikael Sjoberg/Bloomberg The recalled product does not pertain to the branded interchangebale biosimilar, Semglee (insulin ...